Back to Search
SANAM EMANUEL, PHARMD
PHARMD
Pharmacist Clinician (PhC)/ Clinical Pharmacy Specialist
NPI: 1073086013Individual
Specialties, Licenses & Credentials
Pharmacist Clinician (PhC)/ Clinical Pharmacy SpecialistPrimary
Pharmacist — Pharmacist Clinician (PhC)/ Clinical Pharmacy Specialist
Code: 1835P0018X
57664(CA)
Research & Publications (20)
The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases.
PMID 16204078·Cancer Res·2005
7-preclinical
A vascular endothelial growth factor receptor-2 kinase inhibitor potentiates the activity of the conventional chemotherapeutic agents paclitaxel and doxorubicin in tumor xenograft models.
PMID 15322256·Mol Pharmacol·2004
7-preclinical
7-[1H-Indol-2-yl]-2,3-dihydro-isoindol-1-ones as dual Aurora-A/VEGF-R2 kinase inhibitors: design, synthesis, and biological activity.
PMID 18718756·Bioorg Med Chem Lett·2008
7-preclinical
A novel 5-[1,3,4-oxadiazol-2-yl]-N-aryl-4,6-pyrimidine diamine having dual EGFR/HER2 kinase activity: design, synthesis, and biological activity.
PMID 18678484·Bioorg Med Chem Lett·2008
4-observational
4-Amino-6-arylamino-pyrimidine-5-carbaldehyde hydrazones as potent ErbB-2/EGFR dual kinase inhibitors.
PMID 18653333·Bioorg Med Chem Lett·2008
7-preclinical
Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinases.
PMID 18508264·Bioorg Med Chem Lett·2008
7-preclinical
Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors.
PMID 17975007·Mol Pharmacol·2008
4-observational
Design, synthesis, and evaluation of 3,4-disubstituted pyrazole analogues as anti-tumor CDK inhibitors.
PMID 17574416·Bioorg Med Chem Lett·2007
8-other
The transition to an elongation complex by T7 RNA polymerase is a multistep process.
PMID 17548349·J Biol Chem·2007
8-other
Synthesis and evaluation of pyrazolo[3,4-b]pyridine CDK1 inhibitors as anti-tumor agents.
PMID 17532631·Bioorg Med Chem Lett·2007
8-other
4-Aryl-5-cyano-2-aminopyrimidines as VEGF-R2 inhibitors: synthesis and biological evaluation.
PMID 17481894·Bioorg Med Chem Lett·2007
7-preclinical
Synthesis and biological study of 2-amino-4-aryl-5-chloropyrimidine analogues as inhibitors of VEGFR-2 and cyclin dependent kinase 1 (CDK1).
PMID 17317182·Bioorg Med Chem Lett·2007
7-preclinical
Synthesis of 3-(1H-benzimidazol-2-yl)-5-isoquinolin-4-ylpyrazolo[1,2-b]pyridine, a potent cyclin dependent kinase 1 (CDK1) inhibitor.
PMID 17234412·Bioorg Med Chem Lett·2007
8-other
Role of the ABCG2 drug transporter in the resistance and oral bioavailability of a potent cyclin-dependent kinase/Aurora kinase inhibitor.
PMID 17041089·Mol Cancer Ther·2006
7-preclinical
Synthesis and biological study of 4-aminopyrimidine-5-carboxaldehyde oximes as antiproliferative VEGFR-2 inhibitors.
PMID 16979339·Bioorg Med Chem Lett·2006
8-other
Synthesis of 2-amino-4-(7-azaindol-3-yl)pyrimidines as cyclin dependent kinase 1 (CDK1) inhibitors.
PMID 16870444·Bioorg Med Chem Lett·2006
8-other
Synthesis and evaluation of N-acyl sulfonamides as potential prodrugs of cyclin-dependent kinase inhibitor JNJ-7706621.
PMID 16682186·Bioorg Med Chem Lett·2006
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 4777 FIRMAMENT AVE
ENCINO, CA 91436 - Phone
- (310) 592-2177
Quick Facts
- NPI
- 1073086013
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile